Background
Methods
Patients and TMA construction
Age, y, median (range) | 53 (10 ~ 70) |
Gender (male/female) | 290/52 |
Hepatitis infection (no/yes) | 94/248 |
Liver cirrhosis (no/yes) | 38/304 |
AFP, ng/ml, median (range) | 98.5 (0 ~ 60500) |
γ-GT, U/L, median (range) | 57 (7 ~ 693) |
ALT, U/L, median (range) | 39 (8 ~ 949) |
Child-Pugh score (A/B) | 342/0 |
Tumor size, cm, median (range) | 4 (1.0 ~ 21.0) |
Tumor number (single/multiple) | 298/44 |
Tumor capsule (yes/no) | 183/159 |
Tumor differentiation (I/II/III/IV) | 7/248/85/2 |
Tumor thrombi (no/yes) | 249/93 |
TNM stage (I/II&III) | 154/188 |
BCLC stage (A/B&C) | 233/109 |
Prophylactic therapy (none/TACE/immunotherapya) | 342/0/0 |
Post-recurrence therapy (none/TACE/regionalb/resection/othersc) | 221/121/0/0 |
Tissue immunohistochemistry and evaluation system
Western blot analysis
Statistics
Results
Patient profile
Immunohistochemical expression pattern of Sirt3 in paired tumoral and peritumoral tissues
Prognostic significance of Sirt3 for HCC
TTR | OS | |||||
---|---|---|---|---|---|---|
Univariate | Multivariate | Univarate | Multivariate | |||
P value | H.R. (95% CI) |
P value |
P value | H.R. (95% CI) |
P value | |
BCLC stage A | ||||||
γ-GT, U/L (≤54 vs >54) | 0.003 | 1.646 (1.091–2.484) | 0.016 | 0.003 | 1.718 (1.051–2.810) | 0.028 |
AFP, ng/ml (≤20 vs >20) | 0.013 | 1.574 (1.033–2.398) | 0.032 | 0.060 | NA | NA |
Tumor size, cm (≤5 vs >5) | <0.001 | 2.292 (1.515–3.470) | <0.001 | <0.001 | 3.150 (1.952–5.084) | <0.001 |
Tumor number (single vs multiple) | 0.948 | NA | NA | 0.726 | NA | NA |
Tumor capsule (yes vs no) | 0.296 | NA | NA | 0.690 | NA | NA |
Differentiation (well vs poor) | 0.429 | NA | NA | 0.550 | NA | NA |
Mean density score (low vs high) | ||||||
iSirt3(2) | 0.008 | 0.591 (0.396–0.884) | 0.011 | <0.001 | 0.404 (0.251–0.650) | <0.001 |
pSirt3(4) | 0.020 | 0.538 (0.316–0.914) | 0.022 | 0.278 | NA | NA |
TMA assays | ||||||
Age, year (≤52 vs >52) | 0.173 | NA | NA | 0.787 | NA | NA |
Gender (female vs male) | 0.616 | NA | NA | 0.654 | NA | NA |
HBV infection (no vs yes) | 0.903 | NA | NA | 0.168 | NA | NA |
Liver cirrhosis (no vs yes) | 0.803 | NA | NA | 0.225 | NA | NA |
ALT, U/L (≤75 vs >75) | 0.177 | NA | NA | 0.225 | NA | NA |
γ-GT, U/L (≤54 vs >54) | <0.001 | 1.563 (1.121–2.177) | 0.008 | <0.001 | 1.471 (1.003–2.159) | 0.046 |
AFP, ng/ml (≤20 vs >20) | 0.004 | 1.474 (1.048–2.072) | 0.023 | 0.014 | 1.379 (0.936–2.031) | 0.098 |
Tumor size, cm (≤5 vs >5) | <0.001 | 1.830 (1.314–2.549) | <0.001 | 0.000 | 2.919 (2.019–4.220) | <0.001 |
Tumor number (single vs multiple) | 0.057 | NA | NA | 0.069 | NA | NA |
Tumor capsule (yes vs no) | 0.096 | NA | NA | 0.167 | NA | NA |
Differentiation (well vs poor) | 0.162 | NA | NA | 0.124 | NA | NA |
Tumor thrombi (no vs yes) | 0.001 | 1.506 (1.072–2.116) | 0.021 | <0.001 | 1.658 (1.146–2.399) | 0.009 |
TNM stage (I vs II/III) | <0.001 | NA | NA | <0.001 | NA | NA |
BCLC stage (A vs B/C) | 0.001 | NA | NA | <0.001 | NA | NA |
Mean density score (low vs high) | ||||||
iSirt3(2) | 0.011 | 0.705 (0.514–0.967) | 0.031 | 0.001 | 0.558 (0.392–0.795) | 0.001 |
pSirt3(4) | 0.017 | 0.674 (0.450–1.009) | 0.047 | 0.023 | 0.611 (0.381–0.979) | 0.031 |
Variables | iSirt3-TTR | iSirt3-OS | pSirt3-TTR | pSirt3-OS | |
---|---|---|---|---|---|
P value |
P value |
P value |
P value | ||
TNM | |||||
I | 154 | 0.110 | 0.059 | 0.078 | 0.100 |
II/III | 188 | 0.066 | 0.004 | 0.020 | 0.031 |
BCLC | |||||
A | 233 | 0.008 | < 0.001 | 0.020 | 0.278 |
B/C | 109 | 0.690 | 0.366 | 0.204 | 0.020 |
HBV infection | |||||
No | 94 | 0.037 | 0.127 | 0.343 | 0.217 |
Yes | 248 | 0.095 | 0.003 | 0.033 | 0.051 |
Cirrhosis | |||||
No | 303 | 0.029 | 0.003 | 0.046 | 0.059 |
Yes | 38 | 0.151 | 0.076 | 0.131 | 0.148 |
AFP | |||||
≤20 | 132 | 0.075 | 0.078 | 0.371 | 0.334 |
>20 | 210 | 0.104 | 0.006 | 0.049 | 0.079 |
γ-GT (U/L) | |||||
≤54 | 163 | 0.639 | 0.208 | 0.025 | 0.111 |
>54 | 179 | 0.012 | 0.002 | 0.384 | 0.164 |
Tumor size | |||||
≤5 | 229 | 0.127 | 0.045 | 0.094 | 0.093 |
>5 | 113 | 0.046 | 0.003 | 0.062 | 0.108 |
Tumor number | |||||
1 | 297 | 0.011 |
< 0.001 | 0.016 | 0.023 |
≥2 | 44 | 0.547 | 0.903 | 0.566 | 0.585 |
Tumor thrombi | |||||
No | 249 | 0.008 | 0.002 | 0.015 | 0.263 |
Yes | 93 | 0.706 | 0.154 | 0.386 | 0.024 |
Tumor capsule | |||||
Yes | 183 | 0.036 | 0.002 | 0.200 | 0.191 |
No | 159 | 0.209 | 0.124 | 0.035 | 0.064 |
Differentiation | |||||
Well | 255 | 0.007 |
< 0.001 | 0.009 | 0.028 |
Poor | 87 | 0.856 | 0.879 | 0.838 | 0.535 |
Correlation between Sirt3 and clinicopathological features
iSirt3 | pSirt3 | ||||||
---|---|---|---|---|---|---|---|
Characteristics | Low | High |
P value | Low | High |
P value | |
Gender | Male | 124 | 166 | 0.649 | 219 | 71 | 0.632 |
Female | 24 | 28 | 41 | 11 | |||
Age (Years) | ≤52 | 75 | 93 | 0.616 | 135 | 32 | 0.051 |
>52 | 73 | 101 | 125 | 49 | |||
HBV infection | No | 47 | 47 | 0.122 | 68 | 26 | 0.296 |
Yes | 101 | 147 | 192 | 55 | |||
Liver cirrhosis | No | 132 | 172 | 0.877 | 231 | 72 | 0.991 |
Yes | 16 | 22 | 29 | 9 | |||
ALT (U/L) | ≤75 | 127 | 176 | 0.157 | 229 | 73 | 0.613 |
>75 | 21 | 18 | 31 | 8 | |||
AFP (ng/ml) | ≤20 | 51 | 81 | 0.170 | 90 | 42 | 0.005 |
>20 | 97 | 113 | 170 | 39 | |||
γ-GT (U/L) | ≤54 | 63 | 100 | 0.100 | 120 | 43 | 0.275 |
>54 | 85 | 94 | 140 | 38 | |||
Tumor size (cm) | ≤5 | 95 | 134 | 0.342 | 174 | 55 | 0.870 |
>5 | 53 | 60 | 86 | 26 | |||
Tumor number | 1 | 132 | 166 | 0.322 | 229 | 68 | 0.333 |
≥2 | 16 | 28 | 31 | 13 | |||
Tumor thrombi | No | 103 | 146 | 0.244 | 188 | 61 | 0.595 |
Yes | 45 | 48 | 72 | 20 | |||
Encapsulation | Yes | 72 | 111 | 0.115 | 190 | 64 | 0.368 |
No | 76 | 83 | 70 | 17 | |||
Differentiation | Well | 109 | 146 | 0.735 | 136 | 47 | 0.285 |
Poor | 39 | 48 | 124 | 34 | |||
TNM stage | I | 64 | 90 | 0.562 | 122 | 32 | 0.242 |
II/III | 84 | 104 | 138 | 49 | |||
BCLC stage | A | 96 | 137 | 0.258 | 178 | 55 | 0.925 |
B/C | 52 | 57 | 82 | 26 |